Literature DB >> 29850817

Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study.

Jihye Park1,2, Brenna E Blackburn1,2, Patricia A Ganz3, Kerry Rowe4, John Snyder4, Yuan Wan5, Vikrant Deshmukh6, Michael Newman1,6, Alison Fraser5, Ken Smith5, Kim Herget7, Anne C Kirchhoff1,8, Dev Abraham1,9, Jaewhan Kim10, Marcus Monroe1,11, Mia Hashibe1,2.   

Abstract

Context: Thyroid cancer survivors are at high risk of developing multiple cardiac and vascular conditions as consequence of cancer diagnosis and treatment. However, it is still unclear how the baseline and prognostic factors, as well as cancer treatments, play a role in increasing cardiac and vascular disease risk among thyroid cancer survivors. Objective: To investigate the association between potential risk factors, treatment effects, and cardiovascular disease (CVD) outcomes in thyroid cancer survivors. Design, Setting, Patients: Primary thyroid cancer survivors, diagnosed from 1997 to 2012 (n = 3822), were identified using the statewide Utah Population Database. The medical records were used to ascertain information on risk factors and CVD outcomes. Cox proportional hazards models were used to assess the risk of CVD with baseline demographic data and clinical factors.
Results: Among thyroid cancer survivors, age and year at cancer diagnosis, cancer stage, sex, baseline body mass index, baseline comorbidities, and TSH suppression therapy were significantly associated with CVD risk 1 to 5 years after cancer diagnosis. Patients who were male, overweight or obese, older at cancer diagnosis, and diagnosed with cancer since 2005 had an increased risk of CVD compared with patients who were female, had a normal body mass index, were younger at cancer diagnosis, and diagnosed with cancer from 1997 to 1999. Administration of TSH suppression therapy, distant metastases at cancer diagnosis, and a higher Charlson comorbidity index score were associated with an increased CVD risk among thyroid cancer survivors. Conclusions: Our findings suggest that examining the effect of thyroid cancer diagnosis, cancer treatment, and demographic characteristics on the risk of CVD is critical.

Entities:  

Mesh:

Year:  2018        PMID: 29850817      PMCID: PMC6915829          DOI: 10.1210/jc.2017-02629

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Matched designs and causal diagrams.

Authors:  Mohammad A Mansournia; Miguel A Hernán; Sander Greenland
Journal:  Int J Epidemiol       Date:  2013-06       Impact factor: 7.196

Review 2.  Short and long term radiation induced cardiovascular disease in patients with cancer.

Authors:  Kirsten Melgaard Nielsen; Birgitte Vrou Offersen; Hanne Melgaard Nielsen; Merete Vaage-Nilsen; Syed Wamique Yusuf
Journal:  Clin Cardiol       Date:  2017-01-31       Impact factor: 2.882

3.  Effect of radioactive iodine therapy on carotid intima media thickness in patients with hyperthyroidism.

Authors:  Bekir Şanal; İlknur Işık; Mehmet Korkmaz; Cüneyt Kucur; Fatma Can; Türkan Paşalı Kilit; Cüneyt Kahraman; Emre Kaçar; Ahmet Koçak
Journal:  Ann Nucl Med       Date:  2015-10-28       Impact factor: 2.668

4.  Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.

Authors:  Saara Metso; Pia Jaatinen; Heini Huhtala; Anssi Auvinen; Heikki Oksala; Jorma Salmi
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

5.  Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.

Authors:  Iwao Sugitani; Yoshihide Fujimoto
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

6.  Mortality after the treatment of hyperthyroidism with radioactive iodine.

Authors:  J A Franklyn; P Maisonneuve; M C Sheppard; J Betteridge; P Boyle
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

7.  Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy.

Authors:  Robert W Flynn; Sandra R Bonellie; Roland T Jung; Thomas M MacDonald; Andrew D Morris; Graham P Leese
Journal:  J Clin Endocrinol Metab       Date:  2009-11-11       Impact factor: 5.958

8.  Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism.

Authors:  Saara Metso; Anssi Auvinen; Jorma Salmi; Heini Huhtala; Pia Jaatinen
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-17       Impact factor: 3.478

9.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

Review 10.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  Health Phys       Date:  2014-02       Impact factor: 1.316

View more
  9 in total

Review 1.  Thyroid hormone therapy in differentiated thyroid cancer.

Authors:  Giorgio Grani; Valeria Ramundo; Antonella Verrienti; Marialuisa Sponziello; Cosimo Durante
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

2.  The Effect of Gout on Thyroid Cancer Incidence: A Nested Case-Control Study Using a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Mi Jung Kwon; Ji Hee Kim; Joo-Hee Kim; Woo Jin Bang; Sung Kyun Kim; Hyo Geun Choi
Journal:  J Pers Med       Date:  2022-05-27

3.  Among Individuals Irradiated for Benign Conditions in Childhood, Developing Thyroid Cancer Does Not Affect All-Cause Survival.

Authors:  Leonid Vydro; Cari M Kitahara; Jay H Lubin; Arthur B Schneider; Dan V Mihailescu
Journal:  Thyroid       Date:  2020-01-16       Impact factor: 6.568

4.  Cause-specific mortality after diagnosis of thyroid cancer: a large population-based study.

Authors:  Binbin Du; Fang Wang; Leiming Wu; Zheng Wang; Dianhong Zhang; Zhen Huang; Lu Gao; Yapeng Li; Cui Liang; Pengcheng Li; Rui Yao
Journal:  Endocrine       Date:  2020-08-08       Impact factor: 3.633

5.  Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study.

Authors:  Maria Papaleontiou; Debbie W Chen; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Megan R Haymart
Journal:  Thyroid       Date:  2021-04-23       Impact factor: 6.506

6.  Influence of Socioeconomic Status on Incident Medical Conditions in Two-Year Survivors of Adolescent or Young Adult Differentiated Thyroid Cancer.

Authors:  Thomas J Semrad; Qian Li; Melanie Goldfarb; Alison Semrad; Michael Campbell; D Gregory Farwell; Theresa H M Keegan
Journal:  J Adolesc Young Adult Oncol       Date:  2021-01-28       Impact factor: 1.757

7.  Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors.

Authors:  Elena Izkhakov; Joseph Meyerovitch; Micha Barchana; Yacov Shacham; Naftali Stern; Lital Keinan-Boker
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

8.  The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.

Authors:  Yi Dou; Yingji Chen; Daixing Hu; Xinliang Su
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-09       Impact factor: 5.555

9.  Quality of Life of Survivors of Thyroid Cancer Is Not Inferior to That in Subjects without Cancer: Long-Term after Over 5 Years.

Authors:  Jeongmin Lee; Youn-Ju Lee; Dong-Jun Lim; Jung-Min Lee; Sang-Ah Chang; Min-Hee Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-08-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.